In a large population of people with diabetes, the use of GLP-1 receptor agonists was not linked to an increased risk for ...

Eli Lilly’s CEO Dave Ricks cited stocking levels and unexpected market dynamics in Q4 2024 in the GLP-1RA market.

Semaglutide combined with automated insulin delivery enhances glucose control in type 1 diabetes, lowering insulin ...

GoodRx CEO Wendy Barnes outlined the company's priorities at the 2025 JP Morgan Healthcare Conference in San Francisco.

A dietetics professor explains who should and should not embrace the latest weight-loss drugs. Holiday weight gain hits home ...